文章核心观点 - 美国基因检测公司Myriad Genetics与全国性教育和预防性检测组织jscreen建立战略合作伙伴关系 [1] - 通过此次合作,双方将为美国数十万人提供有针对性的外展、基因检测和教育活动 [1] - 此次合作有助于Myriad Genetics扩大其遗传性癌症和生育遗传产品的覆盖范围,增强其作为基因检测领导者的地位 [2][3] 根据相关目录分别进行总结 股价走势 - Myriad Genetics股价在消息公布后下跌2.5%,收于23.33美元 [2] - 但Myriad Genetics股价今年迄今上涨21.8%,而同期行业下跌1.1%,标普500指数上涨22.5% [2] - 尽管最近股价有所下跌,但Myriad Genetics与jscreen的战略合作仍有望带来上行空间 [2] 合作意义 - 此次合作有助于提高教育普及度、可及性和检测便利性,支持个性化医疗和知情决策,让更多人了解和管理遗传性癌症和生育风险 [3] - 双方共同致力于在更广泛范围内提供公平、挽救生命的基因检测服务 [3] - 合作有助于提高患者护理质量,为更多个人提供高质量的基因检测 [3] 行业前景 - 根据先见研究报告,全球基因检测市场规模预计将从2024年的219亿美元增长到2034年的650亿美元,年复合增长率为11.5% [4] - 增长动力来自慢性病患病率上升和技术进步带来的高效创新基因检测产品,以及人们对基因检测好处认知的提高 [4] 最新动态 - 本月,Myriad Genetics与Flatiron Health合作,将其MyRisk遗传性癌症检测纳入Flatiron的OncoEMR平台,方便4,200家医疗机构的8,000多名医生订购和获取检测结果 [5] - 此合作有助于简化生殖系检测工作流程,促进个性化治疗决策,缩短周转时间,最终提高患者护理质量 [5]

Myriad Genetics, Inc. (MYGN) recently announced a joint effort with Ultima Genomics, Inc. to explore its UG 100 sequencing platform and ppmSeq technology. The collaboration will help advance the company’s ability to offer groundbreaking clinical tests in oncology and reproductive genomics.Myriad Genetics has purchased a new UG 100 platform that will soon join other leading sequencing platforms in its new Lab of the Future facility in South San Francisco. The low-cost, low-error sequencing achievable on the ...

SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in breast cancer using Myriad’s Precise® MRD test. Research collaborations include: A study to determine whether circulating tumor DNA (ctDNA) level may predict magnitude of response to pembrolizumab and hormonal therapy in patients with HR-positive ...

SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) platform, today announced a joint effort to explore Ultima’s UG 100™ sequencing platform and its ppmSeq™ technology to advance Myriad’s ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon j ...

SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a third patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.  U.S. patent no. 12,104,212, entitled “Personalized Methods for Detecting Circulating Tumor DNA,” demonstrates Myriad’s continued efforts to advance ...

Myriad Genetics, Inc. (MYGN) is making notable strides in its key strategic areas, which is poised to help it grow in the upcoming quarters. New product introductions and enhancements are gaining traction with customers. There is growing optimism about the company’s huge potential in the oncology space. Meanwhile, the impacts of macroeconomic pressure and fierce rivalry can be worrisome for Myriad Genetics’ performance.In the past year, this Zacks Rank #3 (Hold) company has outperformed both the industry an ...

Myriad Genetics (MYGN) has been gaining share in the hereditary cancer market, with volumes rising 3% year over year in the second quarter of 2024. The company continues to see momentum in its prenatal business as well, growing 25% year over year with a 12% increase in testing volume. This volume growth reflects ongoing initiatives to improve average selling prices (ASPs). The stock carries a Zacks Rank #3 (Hold) currently.The company continues to enhance its customer targeting, digital marketing, and overa ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.W ...

SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor healthcare conferences. The Wells Fargo Healthcare Conference in a fireside chat featuring Scott Leffler, Chief Financial Officer, on Sept. 4, 2024 at 1:30pm ET.The Morgan Stanley Healthcare Conference in a fireside chat featuring Paul J. Diaz, President and CEO, on Sept. 5, 2024 at 7:00am ET. L ...

财务数据和关键指标变化 - 第二季度收入同比增长15%,反映了业务量和每项检测的收入均有所改善 [12] - 毛利润增长17%,调整后EBITDA为1200万美元,调整后每股收益为0.05美元,产生了800万美元的调整后自由现金流 [13] 各条业务线数据和关键指标变化 - 遗传性癌症检测业务包括MyRisk和BRACAnalysis CDx,MyRisk继续保持强劲增长,BRACAnalysis CDx业务有所下降 [21][22][23] - 妇女健康业务第二季度收入同比增长29%,检测量增加12% [25] - GeneSight收入同比增长22%,每项检测收入有所改善 [28] 各个市场数据和关键指标变化 - 美国市场第二季度收入同比增长20%,主要得益于遗传性癌症检测、产前检测和药物基因组学业务的增长 [57][58] - 国际市场第二季度收入同比下降21%,主要受到重组的影响以及日元贬值 [56][57] 公司战略和发展方向及行业竞争 - 公司继续专注于提高客户体验和收入周期管理,通过EMR集成等提高客户便利性和收入 [23][24] - 公司正在加大对研发和技术的投入,以推动创新和提高运营效率,包括实施"未来实验室"计划 [34][35][36][37] - 公司在液体活检和最小残留病检测(MRD)领域取得进展,正在加大相关临床研究和商业合作 [38][39][40][41] 管理层对经营环境和未来前景的评论 - 管理层对公司的长期12%收入增长目标充满信心,认为可以通过提高收费、扩大覆盖范围等方式实现 [51][52][53] - 管理层认为行业整体的付费环境正在改善,公司的收费水平有望保持稳定甚至小幅上升 [46][47][48] 其他重要信息 - 公司出售了EndoPredict业务,预计每年可为公司带来400万美元的利润增加 [54][55] - 公司更新了2024年财务指引,包括收入、毛利率和营业费用的调整 [66][67][68] 问答环节重要的提问和回答 问题1 **Matt Sykes提问** 询问公司在产前检测市场份额提升的驱动因素 [76][77][78][79] **公司回应** 主要来自于现有客户的份额提升,以及新客户的获取,公司正专注于确保获取的客户是有利可图的 [78][79] 问题2 **Colleen Babington提问** 询问公司为何将长期收入增长目标从10%提升至12% [87][88][89][90][91] **公司回应** 公司连续多个季度的强劲增长表现,以及付费环境的改善,都支撑了这一目标的提升 [87][88][89][90][91] 问题3 **Kyle Boucher提问** 询问GeneSight业务的可持续增长空间 [142][143] **公司回应** GeneSight业务仍有双位数增长的空间,同时收费水平也有望小幅提升,支撑整体收入的增长 [142][143]